Skip to main content

Table 2 Pandemic influenza vaccine effectiveness in the surveillance-based and cycEVA studiesa, season 2009-2010, Spain

From: Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010

   Surveillance-based study cycEVA study
  Included population N PIVE % (95%CIb) N PIVE % (95%CIb)
Crude All patients 1326 35 (-38; 73) 436 58 (-81; 95)
  ▪ Delay onset-swabbing less than four days 1175 35 (-45; 74) 381 57(-87; 95)
  EU case definition 701 14 (-131; 72) 377 53 (-109; 95)
  ▪ Delay onset-swabbing less than four days 627 5 (-161; 70) 336 64 (-104; 95)
Adjusted models All patients     
  ▪ full modelc    301 75 (-293; 98)
  ▪ SISSS covariatesd 993 62 (-5; 87) 351 65 (-221; 96)
  All patients and delay onset-swabbing less than four days     
  ▪ full modelc    258 77 (-296; 98)
  ▪ SISSS covariatesd 853 58 (-21; 85) 302 67 (-211; 97)
  EU case definition     
  ▪ full modelc    255 71 (-402; 98)
  ▪ SISSS covariatesd 644 41 (-95; 82) 299 59 (-300; 96)
  EU case definition and delay onset-swabbing less than four days     
  ▪ full modelc    231 72 (-290; 99)
  ▪ SISSS covariatesd 568 48 (-110; 82) 263 68 (-215; 97)
  1. a Cases and controls recruited between week 48/2009 and week 8/2010 and with a delay symptom onset-swabbing less than eight days; b CI = confidence interval; c Adjusted for age group, sex, seasonal vaccination, chronic conditions, previous hospitalizations, number of GP visits in the previous year, functional status, smoking, previous influenza vaccination, risk factors for pandemic influenza, and month of swabbing; d Adjusted for age group, sex, seasonal vaccination, chronic conditions, pregnancy, and month of swabbing; SISSS = Spanish Influenza Sentinel Surveillance.